Many investors tracking fwbi stock are met with confusion when they open their brokerage accounts. First Wave BioPharma, Inc., which famously traded under the ticker symbol FWBI, is no longer active under that name. Over the past few years, a series of complex corporate mergers, rebrandings, and strategic pivots transformed the legacy gastrointestinal (GI) clinical-stage biotechnology firm into a unique multi-asset corporate structure. In May 2024, First Wave BioPharma changed its name to Entero Therapeutics and traded under the ticker ENTO. Then, in late 2025, the company completed a dramatic pivot by acquiring Grid AI Corp, rebranding as GridAI Technologies Corp. and shifting its primary NASDAQ trading symbol to GRDX.
In addition to these ticker migrations, many retail investors frequently confuse FWBI stock with FBRX stock (Forte Biosciences, Inc.) due to their parallel pipelines in the highly competitive and lucrative celiac disease therapeutic space. This comprehensive guide unravels the complex evolution of FWBI stock, reviews its clinical-stage pipeline (including latiglutenase), analyzes its current market status under GridAI Technologies (GRDX), compares its progress with competitor Forte Biosciences (FBRX), and provides actionable insights for retail and institutional investors navigating these stocks in 2026.
The Evolutionary History of FWBI Stock: Ticker Timeline
To understand the current state of FWBI stock, one must trace its corporate history back to its origins, which are marked by several structural changes, historic reverse stock splits, and major acquisitions.
AzurRx BioPharma to First Wave BioPharma (FWBI)
Originally founded as AzurRx BioPharma, the company rebranded to First Wave BioPharma, Inc. to align with its developing portfolio of targeted, non-systemic therapies for gastrointestinal diseases. For several years, the company traded on the NASDAQ Capital Market under the ticker FWBI. During this phase, its research was focused heavily on adrulipase and niclosamide.
However, because of the high costs of clinical trials, the company enacted multiple heavy reverse stock splits to maintain compliance with NASDAQ's minimum bid price rule. These included a 1-for-30 split in August 2022, a 1-for-7 split in January 2023, and a 1-for-20 split in December 2023. These moves heavily consolidated the share counts of legacy retail investors.
The ImmunogenX Merger & Shift to Entero Therapeutics (ENTO) in May 2024
In March 2024, First Wave BioPharma executed a milestone all-stock merger with ImmunogenX, Inc. This transaction added a highly promising, Phase 3-ready oral enzyme treatment for celiac disease called latiglutenase to the company's clinical pipeline. To reflect its renewed focus on advanced gut-targeted biotherapeutics, the combined entity rebranded in May 2024 as Entero Therapeutics, Inc., transitioning its NASDAQ ticker symbol from FWBI to ENTO.
The Pivotal Pivot: Acquiring GRID AI and Rebranding as GridAI Technologies Corp. (GRDX)
In late November 2025, Entero Therapeutics announced a massive strategic shift. The company acquired 100% of GRID AI Corp, a grid-edge artificial intelligence software and controls platform designed for utilities, retail energy providers, and large power users. Effectively transforming from a pure-play clinical-stage biopharma company to a diversified technology and life sciences company, the corporation renamed itself GridAI Technologies Corp. and changed its ticker symbol from ENTO to GRDX on December 1, 2025.
What Happened to Original FWBI Shareholders?
Shares of original FWBI stock transitioned to ENTO and subsequently to GRDX. However, because of the aforementioned stock splits and merger-related conversion ratios, the share counts of legacy investors have been heavily consolidated. If you held FWBI stock, your shares have been converted into GRDX shares according to the respective merger ratios and reverse-split adjustments.
The Legacy Biotech Pipeline: What Happened to Latiglutenase, Capeserod, and Adrulipase?
Even as the parent company transitioned its primary branding to GridAI Technologies (GRDX) to capture the high-growth software and energy infrastructure market, the legacy biopharmaceutical assets remain a central part of its valuation. These assets target massive, underserved healthcare markets.
Latiglutenase (IMGX-003): The Phase 3-Ready Oral Enzyme for Celiac Disease
Latiglutenase is a potentially first-in-class, oral biotherapeutic comprised of two gluten-specific recombinant proteases (a glutenase mixture) designed to degrade gluten proteins in the stomach into non-immunogenic peptides. It is designed to act locally as a supplement to a gluten-free diet, protecting celiac disease patients from accidental gluten exposure, which often occurs due to cross-contamination when dining out.
Clinical studies, including Phase 2 trials, demonstrated that latiglutenase effectively reduces gluten-associated small intestinal mucosal damage (measured by the ratio of villus height to crypt depth) and mitigates symptoms. With Phase 3 trials prepared, latiglutenase is considered a premier late-stage clinical asset in the celiac disease space.
Capeserod: Targeting Gastroparesis
Capeserod is a selective 5-HT4 receptor partial agonist licensed from Roche. It is being evaluated for gastrointestinal motility disorders, specifically gastroparesis. Capeserod offers a targeted approach to accelerating gastric emptying without the systemic cardiovascular risks historically associated with older, non-selective 5-HT4 agonists.
Adrulipase: Recombinant Lipase for Exocrine Pancreatic Insufficiency (EPI)
Adrulipase is a recombinant yeast-derived lipase enzyme biologic designed to enable the digestion of fats and other essential nutrients in patients suffering from exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis and chronic pancreatitis. Unlike the current standard of care—porcine-derived pancreatic enzyme replacement therapies (PERTs)—adrulipase is non-porcine, offering a crucial alternative for patients seeking a highly purified, non-animal-derived option.
The Celiac Disease Landscape: GridAI (GRDX) vs. Forte Biosciences (FBRX)
When researching "fwbi stock," many investors find themselves looking at FBRX stock (Forte Biosciences, Inc.). While these are two completely distinct companies with separate capital structures, they are deeply intertwined in the minds of biotech investors because both are clinical-stage innovators targeting celiac disease—a chronic autoimmune disorder affecting roughly 1% of the global population for which there are currently zero FDA-approved pharmacologic therapies.
Let's break down the scientific and strategic differences between these two contenders:
Forte Biosciences (FBRX) and FB102
Led by CEO Paul A. Wagner, Ph.D., Forte Biosciences is focused on autoimmune and inflammatory diseases. Its crown jewel is FB102, a proprietary anti-CD122 monoclonal antibody. CD122 is a subunit of the intermediate-affinity IL-2/IL-15 receptor expressed on pathogenic natural killer (NK) cells and T cell subsets. By blocking the shared IL-2 and IL-15 signaling pathways, FB102 is designed to halt the proliferation and activation of these tissue-damaging immune cells without disrupting beneficial regulatory T cells (Tregs).
FB102 Clinical Progress in 2026
In June 2025, Forte announced positive topline results from its Phase 1b clinical trial of FB102 in celiac disease. The data showed statistically significant protection against gluten-induced mucosal injury and fewer reported symptoms in patients undergoing an oral gluten challenge. Building on this momentum, the FDA granted Fast Track Designation to FB102 for celiac disease in early 2026. Forte is currently enrolling patients in its Phase 2 "FB102-301" study, with topline results expected in late 2026.
Latiglutenase (GRDX) vs. FB102 (FBRX): Two Radically Different Approaches
- Mechanism of Action: Latiglutenase is an oral enzyme therapy that acts locally in the stomach to break down gluten before it ever reaches the small intestine. It acts upstream of the immune response. FB102, on the other hand, is a systemic biologic (monoclonal antibody) delivered via infusion that targets the downstream inflammatory cascade triggered by gluten, specifically blocking the IL-2/IL-15 pathways that drive villous atrophy.
- Administration: Latiglutenase is taken orally with meals, functioning like a highly sophisticated digestive supplement. FB102 is administered via periodic intravenous infusions.
- Indications: Latiglutenase is strictly localized to celiac disease. FB102 has broad autoimmune applications; in addition to celiac disease, Forte Biosciences is actively evaluating FB102 in Phase 1b clinical trials for vitiligo (with topline data expected in 1H 2026) and alopecia areata (topline data expected in 2026).
Financial Analysis & Market Outlook: Evaluating GRDX and FBRX in 2026
Investing in clinical-stage biotechnology and micro-cap transition stocks requires rigorous financial scrutiny. Let's compare the financial health and market positioning of both GridAI Technologies (GRDX - formerly FWBI/ENTO) and Forte Biosciences (FBRX) in 2026.
GridAI Technologies Corp. (GRDX / Legacy FWBI)
Following its pivot to include GRID AI's software assets, GRDX represents a diversified play. However, as a late clinical-stage developer with pipeline assets like latiglutenase preparing for Phase 3 trials, the capital requirements are substantial. In its recent earnings reports, the company highlighted a dual-revenue strategy: leveraging potential cash-flow generation from its AI-driven energy-infrastructure software platform to help fund its biopharmaceutical pipeline, or potentially out-licensing latiglutenase and capeserod to larger pharmaceutical partners to avoid massive shareholder dilution.
Forte Biosciences, Inc. (FBRX)
Forte enters mid-2026 in a strong capital position relative to many micro-cap peers. According to its Q1 2026 financial results reported in May 2026, the company ended the quarter with $58.2 million in cash and cash equivalents (strengthened by a $150 million public offering priced in April 2026). Its R&D expenses rose to $20.5 million for the three months ended March 31, 2026, up from $12.7 million in the prior-year period. This increase was driven primarily by clinical trial acceleration, including the Phase 2 celiac disease trial and Phase 1b trials for vitiligo and alopecia areata. With approximately 13.9 million shares outstanding, FBRX offers a pure-play, well-funded bet on anti-CD122 immunology.
Frequently Asked Questions (FAQ)
Why is FWBI stock showing as delisted or inactive on my brokerage app?
FWBI is a legacy ticker symbol. First Wave BioPharma rebranded to Entero Therapeutics in May 2024, changing its ticker to ENTO. Then, in December 2025, the company acquired Grid AI Corp and rebranded as GridAI Technologies Corp, moving its ticker to GRDX. If you held FWBI, your brokerage should have automatically updated your shares to GRDX, subject to historical reverse stock splits.
Is GridAI Technologies (GRDX) still developing celiac disease treatments?
Yes. While GridAI Technologies now operates in both AI energy software and life sciences, it continues to hold the clinical development rights to latiglutenase, capeserod, and adrulipase.
What is the relationship between FWBI and Forte Biosciences (FBRX)?
There is no direct corporate relationship. However, they are frequently compared because the legacy asset of FWBI/ENTO (latiglutenase) and the lead asset of Forte Biosciences (FB102) are both high-profile investigational therapies for celiac disease.
What are the upcoming stock catalysts for these companies in 2026?
For GRDX, key catalysts include partnership announcements for its Phase 3-ready latiglutenase or commercial progress in its AI-driven energy software business. For FBRX, the primary catalysts are clinical readouts: topline Phase 1b vitiligo results in the first half of 2026, followed by Phase 2 celiac disease results and Phase 1b alopecia areata results in late 2026.
Conclusion
The saga of fwbi stock is a masterclass in the volatile and fast-paced world of micro-cap biotechnology. From its roots as a GI-focused drug developer, the ticker underwent multiple layers of transformation—first merging with ImmunogenX to acquire latiglutenase (as ENTO), and then absorbing GRID AI to become a diversified tech and biotech play under the ticker GRDX.
For investors looking for a pure-play biopharma bet in the celiac disease and autoimmune arena, FBRX stock (Forte Biosciences) offers a highly focused, well-capitalized clinical pipeline with critical data readouts scheduled throughout 2026. Conversely, those holding GRDX are exposed to a unique hybrid model combining grid-edge AI software potential with the underlying blockbuster potential of a Phase 3-ready celiac disease enzyme supplement. Understanding these distinct pathways and ticker histories is the key to managing risk and identifying alpha in the clinical-stage biotech market.
